Sepracor, Inc. Release: New Medication Helps Relieve Symptoms Associated With Asthma And Copd
NEW YORK, December 12 /PRNewswire/ -- THIS IS A MULTIVU REPORT.
APPROXIMATELY FORTY-ONE MILLION AMERICANS, INCLUDING NINE MILLION CHILDREN, ARE AFFECTED BY ASTHMA AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) - A CHRONIC BREATHING DISORDER OF THE BRONCHIAL AIRWAYS.
NOW THERE'S A NEW MEDICATION THAT HELPS RELIEVE THE SYMPTOMS ASSOCIATED WITH ASTHMA AND COPD. XOPENEX HFA (LEVALBUTEROL) IS A SHORT-ACTING BETA-AGONIST THAT PATIENTS CAN TAKE AT THE FIRST SIGN OF SYMPTOMS, SUCH AS COUGHING, WHEEZING OR CHEST TIGHTNESS. FOR MILLIONS OF CHILDREN AND ADULTS WITH ASTHMA, DAILY ACTIVITIES ARE OFTEN AVOIDED BECAUSE OF THE FEAR OF THESE SYMPTOMS.
DR. WILLIAM E. BERGER, MEDICAL DIRECTOR OF SOUTHERN CALIFORNIA RESEARCHMISSION VIEJO, CA:
"Xopenex HFA inhaler signals an advance in treatment and it's exciting to finally be able to offer my patients something different."
FOR MORE INFORMATION VISIT, WWW.XOPENEX.COM
THIS IS DANIELLE ADDAIR REPORTING.
Important Safety Information
Xopenex HFA is contraindicated in patients with a history of hypersensitivity to levalbuterol, racemic albuterol, or any other component of Xopenex HFA. Xopenex HFA and other beta-agonists can produce paradoxical bronchospasm, which may be life threatening. If additional adrenergic drugs, including other short-acting sympathomimetic bronchodilators or epinephrine, are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects. Due to the cardiovascular side effects associated with beta-agonists, caution is generally recommended for patients with cardiovascular disorders (especially coronary insufficiency, cardiac arrhythmias, and hypertension), diabetes, hyperthyroidism, or convulsive disorders. Do not exceed the recommended dose. Fatalities have been reported in association with excessive use of inhaled sympathomimetic drugs in patients with asthma. Please refer to the complete prescribing information for further information and in regard to potential drug interactions with beta-blockers, diuretics, digoxin, or MAOI and tricyclic antidepressants.
In patients aged 4 to 11 years, the most common adverse events (occurring in greater than 2% of patients and more frequently than patients receiving placebo) were (90 mcg Xopenex HFA and placebo, respectively): accidental injury (9.2%; 5.7%), vomiting (10.5%; 5.7%), bronchitis (2.6%; 0%), and pharyngitis (6.6%; 5.7%).
In patients aged 12 and older, the most common adverse events (occurring in greater than 2% of patients and more frequently than patients receiving placebo) were (90 mcg Xopenex HFA and placebo, respectively): pain (4.0%; 3.6%), dizziness (2.7%; 1.8%), asthma (9.4%; 6.0%), pharyngitis (7.9%; 2.4%), and rhinitis (7.4%; 3.0%).
AUDIO PROVIDED BY: Sepracor Inc.Audio: http://www.prnewswire.com/broadcast/23213/consumer.htmlSepracor Inc.
CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations,1-800-653-5313, EXT. 3 OR EMAIL RADIO@MULTIVU.COM
Web site: http://WWW.XOPENEX.COM/